Atossa Therapeutics (ATOS) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atossa Therapeutics (ATOS) has outperformed Psyence Biomedical (PBM) over the past year, losing 86.4% versus a loss of 94.9%. Atossa Therapeutics is the larger company by market cap ($15.9 million vs $15.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | PBM |
|---|---|---|
| Share price | $1.60 | $2.97 |
| Market cap | $15.92M | $15.80M |
| 1-day change | -8.86% | +3.85% |
| YTD return | -81.98% | -89.90% |
| 1-year return | -86.37% | -94.90% |
| 5-year return | -95.34% | — |
| EPS (TTM) | $-3.92 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-34.77M | $1.01M |
| 52-week high | $14.85 | $73.44 |
| 52-week low | $1.59 | $1.92 |
| Distance from 52-week high | -89.26% | -95.96% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1091.22% | — |
| Average volume | 68.00K | 61.93K |
| Shares outstanding | 9.98M | 5.32M |
| Employees | 16 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ATOS vs PBM FAQ
Which is bigger, Atossa Therapeutics or Psyence Biomedical?
Atossa Therapeutics (ATOS) is larger, with a market capitalization of $15.92M compared with $15.80M for Psyence Biomedical (PBM).
Which stock has performed better over the past year, ATOS or PBM?
ATOS returned -86.37% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.